Teva’s CGRP therapy becomes first approved option for children and adolescent

Promising results support global submissions and priority review by US FDA

Pirtobrutinib meets primary endpoint in CLL/SLL study

Nationwide competition to pilot new models of obesity support

New phase of development targets chronic pain and fibromyalgia

New treatment option now available across all UK nations

New first-line option for patients with pMMR and dMMR tumours in England

Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US

New oral GLP-1 agonist aims to reshape chronic weight management

FDA validation and AI-designed therapies mark major shift in treatment strategy